Korea FDA disciplines labs over herbal tests
This article was originally published in The Tan Sheet
Executive SummarySeven Korean "quality-test laboratories" failed to follow proper procedures and methods in analyzing imported herbal medicine materials, according to South Korea's FDA. The Korea Institute of Oriental Medicine - the only government-invested facility among the labs - will be removed from KFDA's list of designated quality-test labs, after the agency determined the lab carried out faulty inspections of herbals 17 times. The agency warned the other six firms to correct mistakes, which include failure to record examination results thoroughly and improper storage of herbals, Ryu Seung-Rel, a KFDA senior researcher, told 1PharmAsia News. KFDA said there were no problems with the herbals, which were imported from Australia, China, Indonesia, New Zealand and Vietnam
You may also be interested in...
The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.
Correvio's atrial fibrillation drug Brinavess will return to a US FDA advisory committee more than a decade after the agency first declined to approve the drug; FDA still has a series of cardiovascular safety concerns related to the drug and is not convinced by data from the European experience.
FerGene bladder cancer therapy achieved a complete response in more than half of patients in its pivotal trial. The joint venture now looks to commercialization and potential expansion of indications.